INTRODUCTION
In 1950, shortly after completing my Ph.D. degree requirements and joining the faculty of the Animal Science Department at Cornell University, I heard about X-disease, or, more accurately, bovine hyperkeratosis, from Dr. Kenneth McEntee, a pathologist in the Veterinary College at Cornell. Affected animals developed thick skins, resembling armor plate. This was a consequence of their inability to convert carotene to vitamin A [1] ; they lacrimated profusely so that their faces were constantly wet and they lost weight and eventually died. The disease, at first thought to be caused by a virus, was increasing rapidly in the United States and Europe, especially in Germany, prompting the U.S. Department of Agriculture to establish a special research program for the disease. Dr. McEntee and I, along with Dr. Peter Olafson, chairman of the Pathology Department, set out to find the cause of this disease. Luckily, we found some bread crumbs collected from beneath the slicer in a bakery in Burlington, VT, that had been fed to calves that later developed the disease. We extracted the active compound with ether and subjected the extract to column chromatography, testing each fraction for potency by monitoring plasma levels of vitamin A in test calves. Finally, we were able to crystallize the active compound(s) and identify them by spectrophotometry as highly chlorinated naphthalenes [2] . These compounds had been added to heat-resistant lubricants and fire-retardant paints and were also found in a wood preservative made in Germany. When these discoveries were published, and the napthalenes were removed, the disease rapidly disappeared, and few scientists today have ever heard of it.
In retrospect, this early research achievement was a great morale booster, at a critical time in my career. My major research project-the measurement of steroids and gonadotropins in blood and tissues of cattle-was floundering. Plasma levels of steroids, particularly estrogens, proved to be lower than found in other species, and the methods we were using (differential extractions followed by column chromatography and measurement by spectrophotometry) were not adequate. The first comprehensive data correlating plasma luteinizing hormone (LH), estrogen, and progesterone levels during the bovine estrous cycle were not published until 1972 [3] .
The Lesson Learned
Cooperative research with selected scientists in related fields can be very productive.
NUTRITION AND REPRODUCTION
In 1946, when I entered Cornell as a graduate student, the major research interest was in determining if restriction of caloric intake prolonged the life and productivity of cattle and other domestic animals, as it did in rats, as shown by McCay's classic experiments [4, 5] . As an assistant professor, I joined a team of faculty members who designed and carried out the widely publicized ''Three Planes of Nutrition'' studies in dairy cattle. We first showed that heifers fed from birth at 130% of recommended daily allowances showed first estrus and ovulation at 8 mo of age, compared to 12 mo for animals fed 100% of recommended daily allowances and 18 mo for those fed 70% of recommended daily allowances [6] . Pituitary contents of growth and thyrotropic hormones and thyroid hormone secretion were similarly affected [7] . Later studies by Reid and coworkers [8, 9] established that animals fed total digestive nutrient (TDN) restricted diets from birth to first calving lived longer and had higher lifetime milk production than cattle fed normal (100% of recommended TDN allowances) or high (130% of recommended TDN allowances) diets.
Unfortunately, many of the data from the ''Three Planes of Nutrition'' studies were published in Cornell Experiment Station bulletins [6, 9] at a time when these bulletins were losing their popularity as a means of communicating research findings to the scientific community. As a result, these studies were not generally recognized as the first to establish that McCay and Asdell's observations applied to animals other than rodents. Later, the principle that caloric restriction prolongs life was established for many species, including flies, worms, yeast and monkeys [10] .
In 1973 [11] , we were able to show that heifers fed 60% of recommended TDN for three estrous cycles had lower plasma progesterone levels than control heifers fed 100% of recommended allowances for the same period of time. Surprisingly, plasma LH concentrations were higher in the underfed animals, dispelling the notion that decreased ovarian function in energy-restricted animals is due to reduced plasma LH, as appears to be the case in underfed rats. The reduced plasma progesterone concentrations in the energy-restricted animals were correlated with smaller corpora lutea that contained less progesterone. In the same year, we were able to utilize our improved capabilities to accurately measure steroid and gonadotropic hormones in plasma and tissues to show that the association of zinc deficiency with impaired reproduction in several species was not entirely due to its ability to cause reduced food intake [12] .
Our work on nutrition and reproduction was important to the dairy industry in that it encouraged dairymen to pay more attention to lifetime production and discouraged the practice of overfeeding young animals to achieve early maturity.
The Lesson Learned
Choose journals for publication carefully. Select journals that impact the audience you wish to influence and that are likely to exist for a long time.
OVULATION AND CORPUS LUTEUM FUNCTION: THE ROLE OF THE HYPOTHALAMUS
As a graduate student, I learned that the anterior pituitary, through its production of the gonadotropins (follicle-stimulating hormone [FSH] and LH), thyroid-stimulating hormone (TSH), prolactin, growth hormone, and adrenocorticotropic hormone (ACTH), is the ''conductor of the endocrine orchestra.'' However, by 1950, workers such as Everett et al. [13] , among others, were beginning to produce evidence for the existence of a neurogenic (hypothalamic) role in the release of LH and ovulation. Others, including Zuckerman [14] , disagreed. We could not resist getting into the controversy and in 1951 published the first paper demonstrating a hypothalamic influence on pituitary LH release and ovulation in the cow [15] . Subsequent papers [16] [17] [18] [19] contributed to the concept that the hypothalamus controls pituitary function in cows and other species.
In 1953, we discovered that daily injections of oxytocin on Days 2-6 of the bovine estrous cycle prevented normal corpus luteum (CL) formation and function, resulting in shortened estrous cycles approximately 10 days in length [20] . We presented these data at a landmark meeting in the history of reproductive biology [21] , held at West Point, NY, in July 1959, under the auspices of the Population Council and the Planned Parenthood Federation of America. Our presentation precipitated a heated debate between those of us who were convinced that a substance of hypothalamic origin reached the anterior pituitary via the portal vascular system to trigger the release of LH and initiate ovulation and Sir Solly Zuckerman, the general chairman of the conference, who had long argued that the hypothalamus was not involved in any way in the ovulatory process [14] . In a plenary session of the conference, Zuckerman seized on our results with oxytocin to claim that ''the facts presented about oxytocin constituted proof that the portal vessels are an unnecessary speculative adjunct to the FIG. 1. A widely used early schematic drawing to illustrate the transport of a gonadotropin-releasing factor from the hypothalamus to the anterior pituitary by the portal vessels [18] .
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general proposition that the hypothalamus may be involved.'' When called on and with the help from Dr. John Everett (a pioneer in the field), Dr. A.S. Parkes, and others in the audience, I was able to rebut this argument, and most people left the meeting convinced of the existence of a hypothalamic LH-releasing factor delivered to the LH-secreting cells of the anterior pituitary by the portal vascular system (Fig. 1) . Work in this area eventually resulted in the isolation and identification of gonadotropin-releasing hormone (GnRH) (luteinizing hormone-releasing hormone [LHRH]) [22] . The July 1959 meeting at West Point was a turning point in this area of research; more scientists entered the field, and more research funds were made available. The first detailed data on the use of progestins as contraceptives were also reported at this meeting by Gregory Pincus and his associates, and C.R. Austin presented the first data to associate acrosome removal with sperm capacitation.
The Lesson Learned
Successful researchers must be able to explain and defend their findings, orally and in print. New concepts always provoke criticism, and the more important the new concept, the greater the criticisms are likely to be.
CORPUS LUTEUM MAINTENANCE: THE ROLE OF LH
Based on their work with rodents, early investigators [23] thought that prolactin was the major pituitary luteotropic hormone. Consequently, when we published, in 1964 [24] , our first paper showing that LH not only triggers ovulation but also maintains the CL and progesterone secretion as well, it was not well received. At the 13th Easter School at the University of Nottingham in 1966 [25] , I reviewed our work in which we showed that all LH-containing gonadotropin preparations tested (LH, hCG, and a pituitary extract) overcame the inhibitory effects of concurrently administered oxytocin (Days 2-6) on CL weights, progesterone contents, and concentrations. Inactivation of the LH component of these preparations by incubating them with 6M urea rendered them inactive. In contrast, FSH and prolactin failed to overcome the luteolytic effects of concurrently administered oxytocin [24, 26] .
In addition, we presented at this time our first in vitro data obtained by measuring net synthesis of progesterone in incubated slices of luteal tissue after addition of pituitary hormones. Addition of LH alone to the incubation medium stimulated progesterone synthesis to the same extent as all six pituitary hormones (LH, FSH, ACTH, STH, TSH, and prolactin) combined (Fig. 2) .
These and other data cited at the Easter School convinced us that LH is the major luteotropic hormone in the cow. However, Short and Schomberg [25] of Cambridge University remained unconvinced, pointing out their results in six successive experiments in three cows in which they failed to find an increase in blood progesterone concentrations following single injections of hCG in doses ranging from 5000 to 15 000 IU. In response to this challenge, we performed a number of additional experiments [27] [28] [29] , all of which supported the concept that LH is the major pituitary luteotropin, including a demonstration that single injections of bovine LH prolong the life span of the CL [26] . In 1969, in the first issue of Biology of Reproduction, we presented our data to show that injections of bovine anti-LH serum cause CL regression in hysterectomized heifers [30] . During this same time period, workers in G. Niswender's laboratory established that LH is the major luteotropin in the ewe [31] . It is now generally accepted that LH is the major luteotropin in most species, although growth hormone and insulin-like growth factor are also stimulatory [32] .
The Lesson Learned
Isolation of the research problem is all important. In this case, the effect of withdrawal of the luteotropic hormone and activation of the uterine-mediated luteolytic effect were confounded in many experiments.
LUTEOLYSIS
The concept that the uterus produces a luteolytic substance traces to the early studies showing that hysterectomy resulted in prolonged periods of CL maintenance and progesterone secretion in cattle [29, 33, 34] . Furthermore, by 1966 [27] , we had shown that administration of oxytocin did not cause CL regression in hysterectomized heifers as it does in normal cyclic animals. The knowledge that the presence of the uterus is necessary for the luteolytic effect of oxytocin should have alerted us to the fact that the uterus produces a luteolytic substance. The idea that luteolysis may be due to a decline in LH secretion persisted until accurate methods for measuring plasma levels of gonadotropic hormones were developed, and it was clearly shown that this is not the case [35] .
In 1967, while on sabbatical leave in Australia, I spent long hours discussing the possible mechanisms of luteolysis with Dr. James Goding at the University of Melbourne. During these discussions, I showed him some slides of longitudinal sections of the bovine ovarian pedicle that illustrated the presence of very small vessels (vasa vasori) between the uteroovarian vein and the tightly adherent ovarian artery, suggesting the possibility of local veno-arterial transfer of a uterine substance to the ipsilateral CL-bearing ovary. Although venoarterial transfer seemed illogical, Goding decided to test the idea and soon showed that careful dissection of the uteroovarian vein and the ovarian artery and insertion of a block between the two resulted in CL maintenance in the ewe [36] . Goding, a superb surgeon, together with John McCracken, developed a technique for transplanting a CL-bearing ovary to the neck of the ewe. In this operation, the ovarian artery was anastomosed with the carotid and the utero-ovarian vein with the jugular, and the entire preparation was encased in a protective fold of the neck skin. Results obtained with this preparation, reported at the Laurentian Hormone Conference in
Influence of anterior pituitary hormones individually and in combination on progesterone synthesis in vitro by bovine luteal tissue. LH alone stimulated progesterone secretion to the same extent as all anterior pituitary hormones, furnishing additional proof that LH is the hormone primarily responsible for progesterone secretion [28] .
FROM HYPERKERATOSIS TO APOPTOSIS bearing ovary to a site remote from the uterus resulted in prolonged CL maintenance in the ewe, and in 1971 McCracken et al. [38] identified PGF 2a as a luteolytic hormone in the ewe.
In 1967, we concluded-on the basis of our studies showing that neither antibovine LH nor estradiol caused luteal regression in hysterctomized heifers, comparable to that which occurs in normal animals-that the uterus plays a luteolytic role in cattle [29] . The first suggestion that prostaglandin might be involved in luteal regression was made by Babcock in the discussion following our presentation on luteotropic and luteolytic mechanisms in bovine CL at the Brook Lodge Workshop on Ovarian Regulatory Mechanisms, Augusta, MI, in May 1965. We immediately obtained ''prostaglandin'' from the Upjohn Company and tested its luteolytic properties by injecting it directly into the CLs of hysterectomized and normal heifers. The compound was not luteolytic and, in fact, was slightly luteotropic [39] . Only later did we learn from the Upjohn Company that the prostaglandin we tested was PGE 2 , one of a family of prostaglandins derived from arachidonic acid. Following this unfortunate result, we initiated a series of experiments designed to isolate and identify the luteolytic factor(s) from bovine endometrial tissue [40] , resulting in identification of arachidonic acid, the precursor of PGF 2a and other prostaglandins [41] . We were the first to show the preferential transfer of prostaglandin F 2a to the ovarian artery following its intrauterine administration in cattle [42] .
These data from in vivo experiments all supported the concept that luteolysis-both functional and structural in the ewe-is controlled by PGF 2a of uterine origin, which is transferred from the utero-ovarian vein to the ipsilateral ovarian artery by a countercurrent mechanism, thus avoiding its inactivation by the lungs. In the ewe, the lungs are remarkably efficient in inactivation of the prostaglandins. These findings resulted in widespread use of PGF 2a to treat infertility and in schemes developed for control of the estrous cycle in cattle and sheep.
However, as further studies to determine the mode of action of PGF 2a were undertaken, some problems arose. In 1972, we [43] found that infusion of arachidonic acid (AA) (which we had previously identified as the luteolytic factor in extracts of bovine endometrial tissue) into the ovarian arteries of heifers, in which all connections between the uterine horn ipsilateral to the CL were severed, resulted in a marked decline in plasma progesterone. In contrast, plasma progesterone concentrations in vehicle-infused control animals subjected to the same surgical treatment remained high, and their CL persisted for a long time (Fig. 3) . These results showed that, given adequate amounts of AA, the bovine CL can bring about its own regression, probably by PGF 2a synthesis.
In order to facilitate in vitro studies of CL function, we developed a method for separating the luteal cells into a small cell fraction derived from the theca interna and a large cell fraction derived from the granulosa cells [44] . This method allowed the two cell groups to be studied, alone and in combination, and was subsequently used in hundreds of in vitro experiments with dispersed luteal cells of various species. First, it was established by several workers that PGF 2a is luteotropic, not luteolytic, when added to the total dispersed bovine luteal cell population [45] . The small thecal-derived cells were shown to be largely responsible for the luteotropic effects of PGF 2a in vitro.
In 1975, we measured the levels of prostaglandin F (PGF) in bovine endometrium, uterine venous, ovarian arterial, and jugular plasma during the estrous cycle [46] . Increases in uterine vein plasma PGF occurred on Day 15 of the cycle, while plasma progesterone levels were still elevated. However, PGF was not elevated in either the ovarian artery or the jugular vein at any time during the cycle, even when uterine vein levels were greatly elevated. In 1990, we found that AA exerts a dose-dependent effect in mobilizing (Ca 2þ ) in both the small and the large cell preparations, suggesting that it regulates calcium-dependent functions of the CL, including steroid and peptide hormone production and secretion [47] . In 1992, we [48] carried out additional experiments on the effects of AA on the release of the progesterone and oxytocin by the small and large luteal cells. AA caused the release of oxytocin from the large cells and progesterone from both the large and the small cells.
These results suggest that AA plays a key role in bovine CL function, and further study of its role is needed, especially in view of the failure to demonstrate veno-arterial transfer of PGF 2a in several subsequent experiments.
In 1980, we [49] inserted catheters into the uterine veins and ovarian arteries of oxytocin-treated (Days 4-6 of the estrous cycle) heifers and measured progesterone and PGF 2a concentrations in simultaneously collected blood samples. As expected, oxytocin injections depressed progesterone concentrations in jugular vein samples by Day 8. Utero-ovarian vein concentrations of PGF 2a were markedly increased between 30 and 240 min after each oxytocin injection, but no concomitant increases were seen in ovarian arterial blood samples. No one appears to have tested whether veno-arterial transfer of AA occurs in the cow.
These results suggested to us that the luteolytic effects of PGF 2a in vivo are due to its effects on blood flow or to the generation of a compound within the CL that serves as a final common pathway. The cells remaining after separation of the purified small and large cell fractions from collagen dispersed luteal cells include numerous vascular cells (endothelial cells, erythrocytes, leukocytes, and connective tissue cells). These very small (,10 lM in diameter) nonsteroidogenic cells were All connections between the ovarian pedicle and the ipsilateral uterine horn were severed in both control and treated animals. Jugular plasma progesterone concentrations were maintained in vehicle-injected control animals but declined rapidly in AA-treated animals [43] .
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shown to play important roles in CL regression. In 1994, Pate [50] showed that after progesterone production decreases, macrophages invade the CL and initiate apoptotic cell death. Meiden and her coworkers [51] produced evidence that endothelin, from the endothelial cells lining the CL vasculature, may mediate the actions of PGF 2a .
Knowing that the bovine CL cells produces large amounts of nitric oxide (NO), we decided to test the hypothesis that NO is the final common mediator of luteolysis. To test this hypothesis, we employed the elegant technique of microdialysis, which allows both frequent sampling of tissue fluids and injections of treatment compounds. Continuous perfusion of N w -nitro-L-arginine methylester (L-NAME), an inhibitor of nitric oxide synthase into the CL on Days 17 and 18 of the estrous cycle, elevated progesterone and oxytocin concentrations in the perfusate (Fig. 4) and prolonged the estrous cycle through Day 25 [52] . In addition, studies [53] [54] [55] conducted in cooperation with workers on the Faculty of Veterinary Medicine, University of Warmia and Mazury, and the Polish Academy of Sciences, Olsztyn, Poland, we established that NO is produced in the CL and showed that L-NAME blocked the luteolytic action of injected PGF 2a . These and other data suggest that NO is a major mediator of PGF 2a -induced luteolysis.
In 1985, in the Hammond Memorial Lecture [56] and in 1986 in the James R. Goding Memorial Lecture, we [57] presented data to show that prostacyclin (PGI 2 ) plays a luteotropic role in the bovine CL, while products of the lipoxygenase pathway of AA metabolism play luteolytic roles. In 1988, we [45] described the role of (Ca 2þ ) in control of progesterone production in the small and large luteal cells.
There is still a great deal to be learned about the control of CL function, especially about the mechanism of the venoarterial transfer, which now appears to be accomplished with a prostaglandin transporter protein [58] . Controversies in the field still exist, as evidenced by the presentation of two posters at the most recent annual meeting of the Society for the Study of Reproduction (SSR), one claiming that interferon-tau is transported from the uterus to the ovary through the uteroovarian plexus [59] and another claiming that it is not [60] .
The Lesson Learned
Research progress is often driven by development of new techniques. The surgical techniques for transplanting the ovary to the neck, the development of techniques for separating the small thecal-derived and large granulosa-derived cells, and the development of the microdialysis technique all played significant roles in our CL research. But one must not allow the research program to be driven solely by the availability of any single technique.
DEVELOPMENT OF HORMONE ASSAYS
In 1971, we published the first data showing concurrent plasma concentrations of LH and progesterone during the entire bovine estrous cycle [35] . Complete graphs of LH, progesterone, and estrogen plasma concentrations for the entire estrous cycles of cattle, sheep, and swine were presented at the annual meetings of the American Association for the Advancement of Science in 1972 [3] . The accurate measurement of the very low concentrations of estrogen found in bovine plasma was reported in 1973 [61] . The resulting graph (Fig. 5) was widely cited and served as an introduction to so many lectures on hormonal control of ovarian function that it became known as the ''ad nauseum'' slide. In 1983, these data were updated to further emphasize the pulsatile release of LH and the waves of estrogen increase, later shown to be due to waves of follicle growth that resulted in ovulation when the CL regressed and progesterone declined [62] . 
FROM HYPERKERATOSIS TO APOPTOSIS
The development of the LH assay was dependent on the production of highly specific and potent LH antibodies in two mares (Joan and Kay). In 1967, I took this antiserum to Australia, where it was used to develop the first solid-phase radioimmunoassay and to make measurements of ovine LH during the estrous cycle [63] . Because of its potency and specificity and the large volume of antiserum available, this antibody was also widely used in in vivo experiments concerning LH and LHRH (GnRH) effects. The antibody retained its potency and specificity for more than 20 yr.
These data revealed that rapid regression of the CL is a key event on which all other events in the estrous cycle depend. They also showed that regression of the CL does not depend on a decline in circulating LH levels and led to the demonstration of the negative feedback role of progesterone on LH secretion, the positive feedback role of estrogens [64] , and the two celltwo hormone concept of steroidogenesis [43] .
The Lesson Learned
As scientists, we all stand on the shoulders of those who precede us. Development of the data cited required the invention of new techniques (radioimmunoassays for gonadotropin and competitive binding assays for steroids) and the efforts of hundreds of scientists. Many commercial kits are now available for competitive binding and immunoassays, but each must be tested and verified for the laboratory in which it is used.
ESTROUS CYCLE SYNCHRONIZATION
The idea that progesterone injections could be used to control the estrous cycle and produce estrus and ovulation at a predicted time traces back to early studies reported by Ulberg [65] and Trimberger and Hansel [66] in 1950. The variability in the time from the last injection of progesterone to estrus was large, and the conception rates of cows bred at the induced estrus was low (25%) in these early experiments. However, the principle of using the negative feedback of progesterone on pituitary LH release to control the length of the estrous cycle was established. When the orally active progestins became available in 1959, we conducted several trials in which these compounds were fed to control and synchronize the cycles of beef cattle [67, 68] . The most successful of these compounds, medroxyprogesterone acetate (MPA), prevented estrus at daily intakes of about 200 mg. Estrus occurred in 75% of the fed cattle on the third day following its withdrawal. The fertility of the cattle bred at the controlled estrus was 10-15% lower than in control animals. Presentation of these results at the annual meeting of the American Society of Animal Science in 1960 [69] attracted worldwide attention and resulted in hundreds of research papers on cycle synchronization in cattle, sheep, and swine.
At this point, I approached the Cornell administration about filing a patent for our estrous cycle synchronization techniques. I was told, ''Young man, you work for the farmers of New York State, and the information you produce belongs to them.'' Unfortunately, this shortsighted view was prevalent in most state universities at that time. Now we have entered a new era in which research success is often measured by the number of patents obtained and the number of drugs or products brought to the market.
Unfortunately, estrous cycle synchronization following withdrawal of orally active progestins was not precise enough to allow insemination of all treated animals at one preset time, but these studies did establish the fact that short (7-12-day) treatments were more effective than long (15-21-day) treatments. In 1966, Robinson [70] presented, at the 13th Easter School at the University of Nottingham, the results of extensive studies in ewes in which cycle synchronization was achieved by withdrawal of intravaginal sponges impregnated with long-acting progestins. These studies showed that administration of progestins by intravaginal devices is effective and that animals come into estrus 3-5 days following removal of the device. In 1972, we reported at the VII International Congress on Animal Reproduction and Artificial Insemination in Munich, Germany [71] , on the luteolytic effects of PGF 2a in the cow and the possibility of its use in a cycle synchronization protocol. PGF 2a is not effective when given before the fifth day of the cycle, but animals treated with a luteolytic dose between Days 5 and 16 of the estrous cycle return to estrus and ovulate in 3-4 days.
Following the discovery in 1966 by Dziuk and Cook [72] that silastic rubber implants are capable of controlled release of steroids so that sustained blood concentrations can be maintained for predictable periods of time, highly effective progestin releasing intravaginal devices (PRIDs) became available. In 1978, at the Beltsville Symposium in Agriculture, Animal Reproduction [73] , we summarized our work in which we developed an improved treatment for cycle synchronization based on the combined use of PRIDs and PGF 2a . A protocol in which PRIDs were inserted for 7 days and PGF 2a was injected on the sixth day (PRID7-PGF 2a 6) resulted in excellent synchronization (68% of tested animals were in estrus between 60 and 78 h after PGF 2a injection) and a conception rate equal to control animals inseminated during normal estrous cycles. Finally, in 1980, we were able to successfully inseminate cycle-synchronized cattle at a predetermined time without checking them for estrus [74] . These fundamental studies formed the basis for development of even more efficient methods that have enabled the increased use of artificial insemination of beef cattle [75] .
The Lesson Learned
Developing a new concept into a marketable application takes a long time and a lot of money.
EMBRYO DEVELOPMENT
Realizing the potential for in vitro fertilization and transfer of the large number of primordial oocytes found in the ovaries of cattle [76] , sheep, and swine, we began a series of investigations aimed at improving the methods of harvesting, fertilizing, and culturing bovine oocytes. These studies, conducted in a 5-yr period (1993-1998), established a number of important facts concerning the control of early bovine embryo development. By 1992, the development of embryo coculture systems, using various helper cells ranging from oviduct epithelial cells to chick embryo amnion, was well established [77] , but little information was available on the biochemical interactions involved. In 1993, we [78] determined that the stimulatory effect of bovine oviduct epithelial cells on development of early bovine embryos requires platelet-derived growth factor (PDGF). In vitro matured and fertilized bovine embryos were not able to develop beyond the eight-cell stage in the absence of PDGF. The 8-16-cell stage represents the ''block'' stage in bovine embryo development and was thought to correspond to the genomic transition from maternal to zygotic control [79] . We were able to show that the beneficial effects of culturing embryos in groups, rather than individually, were due to PDGF produced by the embryos in culture and that development of embryos beyond the 16-cell stage to the morula and blastocyst stages required transforming growth HANSEL factor (TGF) in the culture medium. Development of eight-cell embryos cultured singly in a defined medium containing PDGF, TGF, arachidonic acid, b mercaptoethanol, and glutathione was achieved for the first time [80] .
In an in vivo experiment, high environmental temperature and humidity resulted in a marked decline in the quality of oocytes harvested from Bos taurus cows and markedly decreased their ability to develop in vitro; in contrast, oocytes collected from Bos indicus cows subjected to heat and humidity exhibited normal morphology and developmental capabilities [81] .
Unexpectedly, in 1997, we found that addition of an NO scavenger (hemoglobin) or an NO synthase inhibitor (L-NAME) to the culture medium consistently enhanced development of bovine embryos to the eight-cell, 16-cell, morula, and blastocyst stages [82, 83] . This work led to the granting of two patents and established a workable bovine embryo culture system.
The Lesson Learned
The unexpected findings are sometimes more important than the expected results.
REPRODUCTION IN NONRUMINANT SPECIES
The cow and ewe proved to be excellent models for studies of CL function and our work with dairy cattle was supported for many years by both the National Institutes of Health and the U.S. Department of Agriculture. However, our laboratory also contributed essential information to the understanding of reproduction in at least three other domestic animal speciesdog, mink, and alpaca.
Our first paper on reproduction in the dog, also reported in the first issue of Biology of Reproduction in 1969 [84] , concerned the induction of female pseudohermaphroditism by methyl testosterone injections during pregnancy. In 1975, Concannon et al. [85] , presented data correlating the plasma levels of estrogen, LH, and progesterone during the complete ovarian cycle of the bitch. These data were very useful in further studies on reproduction in the dog [86, 87] and are still frequently cited. In 1981 [88] , workers in our laboratory reported that treatment of bitches with the contraceptive drug medroxyprogesterone acetate (MPS) for periods of 1 yr or more prevented estrus but also induced the dose-related development of multiple, large (75 mm in diameter) mammary gland nodules. Most of these large nodules consisted of benign mammopathies (lobular hyperplasia and simple and complex adenomas) that have histopathological counterparts in human breast diseases. These findings stirred yet another controversy and stimulated years of additional research sponsored by drug companies and the National Institutes of Health before the drug was finally approved for human use by the Food and Drug Administration. However, the results of one of these early experiments remain unexplained [89] ; beagle bitches treated with high doses of MPA for 17 mo had elevated serum levels of growth hormone and developed acromegalic symptoms, including thickening and folding of the skin, reduction of fat depots, liver enlargement, and liver lesions in addition to the mammary gland nodules. Serum cortisol levels were reduced in the progestin-treated animals, but prolactin concentrations were unchanged.
In 1980, we [90] showed that treatment of mink with prolactin during the period of embryonic diapause advanced implantation time and hastened the onset of luteal-phase progesterone secretion. Treatment with ergocryptine, a drug that inhibits prolactin secretion, had the opposite effect. In the following year (1981), the idea that prolactin is the pituitary hormone responsible for termination of the embryonic diapauses was firmly established by Murphy et al. [91] , who demonstrated luteal activation and implantation in hypophysectomized-prolactin-treated mink in embryonic diapause. Hypophysectomized untreated mink displayed no luteal activation or embryo implantation. Rising levels of prolactin, induced by increasing hours of daylight, is solely responsible for ending embryonic diapauses in the mink. This information is of great importance to mink breeders who have discovered that a second mating of mink during the embryonic diapause yields a 10-15% increase in the number of kits born.
In 1970, we [92, 93] published the first data on CL function and progesterone secretion in the alpaca. The alpaca is an induced ovulator, but the CL formed after infertile mating and ovulation do not remain active for a long time. After attaining full size and secretory activity about 8 days after ovulation, the CL of nonpregnant animals decline rapidly in weight and secretory activity by Day 13. This is an active luteolytic process and involves the uterus. Interestingly, the luteolytic effect of the right uterine horn is local only, while that of the left uterine horn is both local and systemic [94] . Although ovulation occurs with equal frequency in both ovaries, 98.4% of pregnancies are found in the left uterine horn. These studies, which were carried out at the Alpaca Experiment Station at La Raya, Peru, at an altitude of 4300 m above sea level, were of immediate use to the alpaca breeders, who then realized that animals that failed to conceive to first breeding could often be successfully rebred 13 days after the infertile mating. Hematoxylin-eosin stained sections of PC-3 xenografts from nude mice treated with saline or Hecate plus LHRH contained predominantly viable cells, while tumors from mice treated with conjugated LHRH-Hecate showed a high degree of necrosis [104] .
FROM HYPERKERATOSIS TO APOPTOSIS

The Lesson Learned
We can learn a lot by studying reproduction in animals that reproduce efficiently under a variety of climatic conditions.
REPRODUCTIVE HORMONES AND CANCER
In 1997, my wife died of ovarian cancer, and I came to realize how few really effective cancer drugs, particularly drugs that target specific cancers, were available. Many of the drugs being used were designed to kill all rapidly dividing cells and, as a result produced many serious side effects. During this period, I attended a symposium in Poland, where Dr. Rao [95] discussed the expression of gonadotropin and gonadotropin-releasing factor (GnRH or LHRH) receptors by various cancer cells. At that time, I realized that conjugates of lytic peptides and segments of the b chain of the gonadotropins LH, human chorionic gonadotropin, and FSH or LHRH might be used to target and destroy cancer cells that express the appropriate receptor.
The lytic peptides are linear, alpha-helical, amphipathic, membrane-disrupting compounds containing less than 40 amino acids [96] . We coupled several synthetic lytic peptides (Hecate, Phor14, and Phor21) with a 15-amino-acid segment of bCG or with LHRH ( Fig. 6 ) and tested the effect of each conjugate in vitro and in vivo on prostate [97] [98] [99] , breast [100, 101] , ovarian [102] , testicular [103] , and pancreatic cancers (unpublished data).
In all cases, both the bCG and the LHRH-lytic peptide conjugates were effective in reducing tumor volume and weight in the nude mouse model bearing xenografts of each of these human cancer cell lines (Figs. 7 and 8) . Each of these lytic peptide conjugates was also shown to be effective in seeking out and destroying metastatic cancer cells [104] (Fig.  9) . The lytic peptide conjugates all act by disintegrating cancer cell membranes and causing cancer cell necrosis.
We have recently shown that pretreatment of pancreatic cancer xenograft-bearing nude mice with FSH increases the ability of the LHRH-lytic peptide conjugate, EP100, to cause tumor regression [105] . This finding suggests that FSH upregulates LHRH receptors and provides a potential method for insuring that patients chosen for treatment overexpress LHRH receptors.
The use of LHRH or segments of the b chain of CG, LH, or FSH to target cancer cells is not limited to lytic peptide conjugates. For example, we have found that administration of a conjugate of LHRH and curcumin, the active ingredient of the Asian spice turmeric, to nude mice bearing human pancreatic cancer cell xenografts caused a significant reduction in tumor weights and volumes. Unlike the lytic peptide conjugates, the LHRH-curcumin conjugate acts by enhancing apoptosis [106] . Curcumin has long been suspected to have anticancer potential, but it is so insoluble that human patients cannot ingest enough to be effective. Surprisingly, the LHRHcurcumin conjugate is highly soluble and can be injected. LHRH-curcumin may be useful in treating pancreatic ductal adenomas, which are invariably lethal. 
HANSEL
The rights to develop the lytic peptide conjugates have been acquired by Esperance Pharmaceuticals, Inc., and this company recently completed phase I clinical trials with their leading drug, EP-100, a conjugate of LHRH and a lytic peptide. Esperance, with financial support of a large pharmaceutical company, is now beginning phase II clinical trials with EP-100.
The Lesson Learned
Yogi Berra said it best: ''When you come to a fork in the road-take it!'' Embarking on a career in cancer research at an advanced age made little sense, yet it proved to be remarkably successful.
CONCLUDING REMARKS
These citations are but a small portion of the contributions of the 100 or more graduate and postdoctoral students who worked in my laboratory over the years. I apologize for the omission of many contributions that could not be cited because of space limitations. Over the years, I have been remarkably lucky in choosing successful graduate and postgraduate students (Fig. 10) . Many of the students listed in the references have contributed to the Society as presidents, directors, awardees, and committee members. I enjoy talking to young scientists at meetings, such as the SSR annual meetings, who often explain to me that they are ''scientific'' grandsons or granddaughters or, in some cases, scientific great-grandsons or great-granddaughters. Needless to say, I am proud of their contributions that continue to sustain and enrich the Society. I am equally proud of my own service to the Society, as a founder, director, president, and recipient of the Carl G. Hartman and Distinguished Service Awards.
I do have concern about the extent to which research carried out by Society members is shifting from in vivo to in vitro studies. Unfortunately, this trend exists in other societies as well. I am often asked to judge posters for awards at scientific meetings, and I frequently ask poster presenters how their research fits into the overall physiology of the organism they are studying or what application their findings might have in agriculture or medicine. All too often, the answers I get to these questions are inadequate. The poster presenters often have no idea how their work relates to physiology and, more important, fail to see the importance of the question. Are we training a generation of scientists who think that results of an in vitro experiment are always applicable to the whole animal and who lack interest in looking for applications of their results to practical problems? I hope not.
